908 Devices
NASDAQ: MASSBoston, US · Founded 2012 · Delaware corporation · 211 employees on LinkedIn · Public · 8 known investors
908 Devices manufactures handheld mass spectrometry and chemical analysis devices for rapid detection in defense, security, and hazardous materials response applications. The company serves customs agencies, law enforcement, first responders, and military organizations requiring real-time chemical identification for explosives, toxic substances, and illicit drugs.
Also known as 908 Devices Inc. · MASS
Founders & leadership
908 Devices was founded in 2012 by Kevin J. Knopp, PhD, Christopher Brown, and Kevin Knopp.
Board
Investors · 8
Also in the syndicate · 3
Reported raises · per SEC filings
Form D private placements$53.1M disclosed across 3 of 5 rounds · 2012–2019
▶$17.5MraisedApr 2019 · 12 investors · Other TechnologyRule 506(b)
- Kevin KnoppExecutive Officer, Director
- Joseph GriffithExecutive Officer
- Christopher BrownExecutive Officer
- J. Michael RamseyDirector
- Sharon KedarDirector
- Kevin CrandellDirector
- Mark SpotoDirector
- Nicolas BarthelemyDirector
- Kevin HrusovskyDirector
- Offering amount
- $17.5M
- Amount sold
- $17.5M
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$24MraisedSep 2018 · 13 investors · Other TechnologyRule 506(b)
- Kevin KnoppExecutive Officer, Director
- J. Michael RamseyExecutive Officer
- Nicholas BarthelemyDirector
- Kevin HrusovskyDirector
- Mark SpotoDirector
- Kevin CrandellDirector
- Offering amount
- $24M
- Amount sold
- $24M
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.6MraisedMay 2015 · 8 investors · Other TechnologyRule 506(b)
- J. Michael RamseyDirector
- Christopher BrownExecutive Officer
- Kevin HrusovskyDirector
- Joseph Griffith IVExecutive Officer
- Corey SteffekDirector
- Mark SpotoDirector
- Kevin KnoppExecutive Officer, Director
- Keith CrandellDirector
- Amount sold
- $11.6M
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026908 Devices Inc. is a commercial-stage technology company that designs and manufactures handheld chemical analysis devices used to detect, identify and monitor hazardous substances in health, safety and defense applications. Its portfolio spans multiple analytical techniques: MX908, a battery-powered handheld mass spectrometer for trace-level identification of narcotics, explosives and hazardous materials in solid, liquid, gas and aerosol form; NIRLab, a near-infrared spectroscopy drug field-test device that identifies and quantifies potency of common drugs and links results to a real-time intelligence platform; VipIR, which combines FTIR and Raman with what the company calls Smart Spectral Processing for bulk solids and liquids; XplorIR, a handheld gas/vapor analyzer that identifies and quantifies unknown gases at ppm levels; ProtectIR, a compact handheld FTIR for bulk solid and liquid identification with condensed-phase mixture analysis; ThreatID, an FTIR multi-threat identifier requiring no recalibration between sampling modules; and InterceptIR, a gas detector that integrates onto robotic and unmanned platforms for remote monitoring [0][2][3].
The company historically also sold desktop and life-science instruments, including the ZipChip separation platform for mass spectrometry sample analysis, the Rebel desktop bioprocess analyzer, MAVEN and MAVERICK. Following the March 2025 divestiture of its desktop bioprocessing portfolio to Repligen, 908 Devices refocused entirely on its handheld chemical detection business under a strategy described as "908 2.0" [1][6][7].
Application areas marketed by the company include customs and borders, defense and explosives/EOD, fire and hazmat/CBRN response, narcotics investigation, and continuous area monitoring. Devices combine analytical hardware with analytics and machine-learning-based processing intended for operation by non-specialist users in the field [0][1][2].
Founding story
The founding team set out in 2012 to shrink mass spectrometry from a laboratory bench instrument into a handheld device, aiming to democratize the technology for non-laboratory users. The company name refers to 0.908, a point of stability and instability within ion trap mass spectrometers. Co-founders identified across sources include Dr. Kevin J. Knopp (CEO), Dr. J. Michael Ramsey, Dr. Christopher David Brown (CTO and VP of R&D) and Steve Araiza [1][6][7].
Business model
908 Devices sells purpose-built analytical instruments, along with related consumables, software/intelligence platforms and service and support, to government and commercial end users. A third-party analysis reports recurring revenue reached 35% of total revenues in Q3 2025, indicating a mix of instrument sales plus ongoing consumable/service streams [6]. Support is offered via a 24/7/365 service line, and the company also runs a channel/distributor motion, soliciting partners with law enforcement customer relationships for the NIRLab product line [0][3][4].
Revenue derives primarily from sales of handheld analytical devices to public-safety, defense and customs organizations, supplemented by recurring revenue (35% of total revenues in Q3 2025). Full-year 2025 revenue from continuing operations was guided to $54.0-$56.0 million, representing 13-17% growth over the prior year, with a target of positive Adjusted EBITDA in Q4 2025 [6].
Traction
ZipChip was reported as adopted by all of the top 10 global biopharmaceutical companies as of the 2019 Series E, and MX908 was described as in use by first response and military organizations worldwide [5]. Post-pivot, full-year 2025 continuing-operations revenue guidance was $54.0-$56.0 million (13-17% growth), recurring revenue was 35% of total revenues in Q3 2025, and the company reported $112.1 million in cash with zero debt as of Q3 2025 [6]. The company reported Q2 2026 results and raised the low end of its 2026 revenue outlook [0][2]. Products have received multiple industry awards, including R&D 100 Awards (ZipChip, MAVEN, MAVERICK), The Scientist Top 10 Innovations (ZipChip), The Analytical Scientist Innovation Awards (REBEL, MAVERICK), ASTORS Homeland Security gold awards (Aero Module, MX908 Beacon) and a Firehouse Innovation Award (XplorIR) [1].
Latest developments
908 Devices acquired NIRLAB AG in 2026 and has added the NIRLab drug field-test device to its product line, actively recruiting channel partners with law enforcement reach for it. It launched VipIR in 2025 after divesting its bioprocessing analytics portfolio to Repligen the same year. In August 2026 the company reported second quarter 2026 financial results and raised the low end of its 2026 revenue outlook, and scheduled appearances at the Canaccord Genuity 46th Annual Growth Conference and the 17th Annual Midwest IDEAS Investor Conference [0][1][2].
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
The company positions itself in the point-of-need segment of the analytical instrumentation market, described by one third-party source as a $100+ billion market, and at the time of its 2019 Series E it described itself as the most well-resourced upstart in the multibillion-dollar mass spectrometry market. As of November 2025 its market capitalization was reported at approximately $326 million, while a separate wiki-style profile listed a market cap of $427.80 million as of 2026 [5][6][7].
Differentiation rests on packaging laboratory-grade analytical techniques—mass spectrometry, FTIR, Raman and NIR—into rugged, handheld, battery-powered instruments operable by non-specialists at the point of need, with onboard analytics and machine learning, no recalibration between sampling modules (ThreatID), and results in seconds. Following the 2025 divestiture the company is focused solely on the handheld chemical detection portfolio [0][1][2][3][6].
Technology
Core technologies include miniaturized ion-trap mass spectrometry (the company name references 0.908, a stability/instability boundary in ion trap mass spectrometers), FTIR and Raman spectroscopy, near-infrared spectroscopy, and microfluidic high-speed separations (ZipChip). These are paired with onboard analytics and machine learning to deliver identification results in seconds from handheld, field-deployable form factors; the MX908 packages mass spectrometry into a device weighing under 10 pounds [0][1][2][6][7].
Go-to-market
Direct sales and support (sales/order and 24/7 service lines) combined with distributor and channel partner recruitment, particularly for the NIRLab line into law enforcement. The company markets heavily through sector conferences and training events such as the National Interdiction Conference, the Pennsylvania Hazmat Conference and NCT USA (CBRNe preparedness), plus webinars and investor conferences [0][2][3][4].
First responders, fire and hazmat teams, law enforcement and narcotics investigators, corrections departments, customs and border agencies, EOD and military/defense organizations. Cited users include the Ohio Attorney General Bureau of Criminal Investigation, the Minnesota Department of Corrections, the Middlesex County (NJ) Hazardous Materials Unit, Charlotte Fire, the Marion, OH police department and Belgian federal justice authorities [0][2]. Earlier in its history the company also served life-science and biopharmaceutical customers, with ZipChip reported as adopted by all of the top 10 global biopharmaceutical companies [5].
Geography
Headquartered in the Boston area with a corporate office at 44 3rd Avenue, Burlington, MA and a manufacturing center at 41E Eagle Road, Danbury, CT [4]. Additional sites referenced include the original Boston, MA facility, life-science R&D in Morrisville, NC and bioanalytics R&D in Braunschweig, Germany [1]. A third-party profile states operations across the Americas, Europe, the Middle East, Africa and Asia Pacific [7].
History
Founded in Boston in 2012 to miniaturize mass spectrometry for chemical detection. ZipChip launched in 2016 and the flagship MX908 handheld mass spectrometer in 2017. The company expanded its ISO9001 Boston facility to 30,000 sq ft in 2018 and launched REBEL in 2019. It went public on Nasdaq under the ticker MASS in 2020, launched the MX908 Aero Module in 2021, and acquired TRACE Analytics GmbH in 2022. In 2023 it launched MAVEN, MX908 Beacon and MAVERICK and expanded R&D facilities in Morrisville, NC and Braunschweig, Germany. In 2024 it acquired RedWave Technology, expanded R&D and production in Danbury, CT, and launched the XplorIR Quantification Package. In March 2025 it divested its desktop bioprocessing analytics portfolio to Repligen for approximately $70 million, launched VipIR, and in 2026 acquired NIRLAB AG [1][6]. One third-party wiki states the company was founded in 2011 to commercialize high-speed separations, mass spectrometry and microfluidics, conflicting with the 2012 founding date given elsewhere [7].
Risks & controversies
Sources describe the 2020 IPO as introducing quarterly earnings pressure and the need for a clear path to profitability, and note the company was still targeting positive Adjusted EBITDA only in Q4 2025. The business is concentrated in government, public-safety and defense procurement channels, and the 2025 divestiture removed the life-science/bioprocessing revenue base, leaving the company dependent on a single handheld product line. Sources also conflict on founding year (2011 vs 2012) and market capitalization figures [1][6][7].
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 20
launches, deals, and filingsAcquisition added the NIRLab NIR spectroscopy drug field-test device and real-time intelligence platform to the portfolio.
908 Devices sold its bioprocessing/desktop analytics portfolio to Repligen Corporation, generating approximately $70 million in cash and refocusing the company on handheld chemical detection ('908 2.0' strategy).
$70M source ↗
Chemical analyzer combining FTIR and Raman with Smart Spectral Processing for bulk solids and liquids.
Acquisition significantly expanded the handheld portfolio with Fourier-Transform Infrared (FTIR) devices.
MAVERICK launch; received The Analytical Scientist Innovation Award and an R&D 100 Award.
Acquisition expanded the company's technology base and bioanalytics R&D footprint.
Aerosol sampling module for MX908; received ASTORS Homeland Security Awards Gold.
IPO on the Nasdaq Global Market raising capital to scale operations, R&D and market expansion.
Round led by Northpond Ventures with Sands Capital Ventures and follow-on from ARCH Ventures, Razor's Edge Ventures, Saudi Aramco Energy Ventures, Schlumberger, Tao Capital Partners and Casdin Capital; brought total funding to $70M. Northpond's Sharon Kedar joined the board.
$17.5M source ↗
Desktop bioprocess analyzer; received The Analytical Scientist Innovation Award.
Expansion to a 30,000 sq ft ISO9001 facility in Boston, Massachusetts.
Flagship handheld, battery-powered mass spectrometry device for trace-level chemical detection; received Instrument Business Outlook Gold Award.
First commercial product, a high-resolution/high-speed separation platform for mass spectrometry sample analysis; received an R&D 100 Award and The Scientist Top 10 Innovations Award.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 8
primary sources listed
- 908 Devices908devices.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does 908 Devices do?
- Nasdaq-listed maker of handheld mass spectrometry and spectroscopy devices for chemical detection at the point of need.
- Who founded 908 Devices?
- 908 Devices was founded by Kevin J. Knopp, PhD, Christopher Brown, Kevin Knopp in 2012.
- Who are 908 Devices's investors?
- 908 Devices's investors include ARCH Venture Partners, Razor's Edge Ventures, UTEC, Aramco Ventures, Northpond Ventures.
- How much funding has 908 Devices raised?
- 908 Devices has disclosed $53.1M raised across 3 of its 5 known rounds.
- Is 908 Devices publicly traded?
- Yes — 908 Devices trades on NASDAQ under the ticker MASS.
- Where is 908 Devices headquartered?
- 908 Devices is headquartered in Boston, US.